UBS Pharma Forum Yields M&A Sound Bites

Cohen, Judy Radler
May 2006
Mergers & Acquisitions Report;5/1/2006, Vol. 19 Issue 17, p3
Reports on speculations regarding the possible spinoff of Rosemont Pharmaceuticals by Savient Pharmaceuticals Inc. Market capitalization review of Rosemont conducted by Savient according to remarks by CEO Christopher Clement at the 2006 UBS Global Specialty Pharmaceuticals Conference in New York; Decision of Savient to hire Citigroup rather than former advisor UBS for the Rosemont mandate.


Related Articles

  • PHARMACEUTICAL TECHNOLOGIES / LIFE SCIENCES: CHRISTOPHER CLEMENT.  // njbiz;6/23/2008, Vol. 21 Issue 26, Special section p23 

    The article profiles Christopher Clement, chief executive officer (CEO) of Savient Pharmaceuticals Inc. It says that the firm has been focused in the development and commercialization of pegloticase, a drug for treatment-failure gout, and Christopher has guided the company with an emphasis on...

  • PEOPLE. McGuire, Stephen // Medical Marketing & Media;Sep2004, Vol. 39 Issue 9, p111 

    This article presents information on the promotion and recruitment of executives in the health industry. Christopher Clement has been promoted to chief executive and acting chairman at Savient Pharmaceuticals Inc. Clement was president and chief operating officer. He succeeds Sim Fass, who...

  • Pharma firm seeks a CEO to entice buyers. Kaltwasser, Jared // njbiz;1/3/2011, Vol. 24 Issue 1, p3 

    The article reports that the Savient Pharmaceuticals Inc. in East Brunswick, New Jersey is searching for its new chief executive officer (CEO).

  • Savient names CEO to launch new drug. Kaltwasser, Jared // njbiz;1/31/2011, Vol. 24 Issue 5, p3 

    The article announces the appointment of John H. Johnson as chief executive officer (CEO) of the Brunswick, New Jersey-based Savient Pharmaceuticals Inc.

  • Developments Update.  // PharmaWatch: Cancer;Feb2005, Vol. 4 Issue 2, p5 

    The article presents several updates related to the latest developments of antineoplastic agents. Bavarian Nordic AS announced the establishment of its cancer vaccine research subsidiary, BN ImmunoTherapeutics Inc. Savient Pharmaceuticals Inc. signed an exclusive agreement between Rosemont...

  • Seeking a buyer as drug goes to market. Kaltwasser, Jared // njbiz;11/1/2010, Vol. 23 Issue 44, p3 

    The article reports on the plan of Savient Pharmaceuticals Inc. to move forward with the launch of its lead drug Krystexxa for the treatment of chronic gout in adults.

  • Savient Shares Tumble on Extension Safety Data.  // Bioworld Week;11/3/2008, Vol. 16 Issue 44, p3 

    The article reports on the decrease in the shares of Savient Pharmaceuticals Inc. following the company's presentation of data on its pegloticase (Puricase) for treatment-resistant gout in the U.S. Analysts' main concerns are the safety issue of the drug and the size of its market. The company...

  • Savient sells its biologics.  // Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p2 

    Reports that Savient Pharmaceuticals Inc. has shed its global biologics manufacturing operations to two subsidiaries of Lausanne, Switzerland-based biopharmaceutical Ferring Holding SA. Amount that will be paid by Ferring; Global rights gained by Ferring to human growth hormone and other products.

  • Pharmaceuticals focus of DFB. Bassett, Elizabeth // Fort Worth Business Press;8/24/2009, Vol. 24 Issue 31, p9 

    The article profiles DFB Pharmaceuticals Inc. which is included in the Top 100 Public and Private Companies in the Tarrant County, Texas area as compiled by "Fort Worth Business Press." The three companies that comprise DFB include Healthpoint, DPT Laboratories and Phyton Biotech. H. Paul...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics